Strategy to treat AIDS patients in Africa with less drug, reduced toxicity set for clinical test

July 01, 2003

PHILADELPHIA - An innovative AIDS-treatment strategy that would reduce the overall amount of drugs needed to control a patient's HIV infection by about a third has been approved for clinical testing in South Africa. The collaborative international study, led by researchers at The Wistar Institute and the University of Witwatersrand in South Africa, brings together scientists and physicians from a number of institutions in both countries. Funding of approximately $3 million for the five-year project begins today and comes from the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health.

If successful, the new strategy - a structured stop-and-start drug regimen - would permit health agencies in resource-poor countries overburdened by the AIDS epidemic to extend care to many more patients with the same quantity of drugs, thus saving lives. Individual patients on the protocol in both the developed and developing worlds would benefit from reduced exposure to the toxicities associated with HIV drugs.

That's the good news. The bad news is that funding guidelines set by the NIAID do not permit that agency, which oversees most U.S.-supported AIDS research, to cover the cost of the drugs needed to conduct any AIDS research study. So the researchers will need to find the money for the needed drugs from an alternate source. Even at the reduced prices at which drug companies are now making their HIV drugs available in South Africa and other parts of the developing world, the cost could be well over $1 million - a significant burden for a team of nonprofit scientists. (In the U.S., the same drugs would cost approximately ten times as much.) The consequence of this situation is that this promising study with important public-health implications may never happen.

"As an academic research institution, we've gone as far as we can go with the government," says Luis J. Montaner, D.V.M., D.Phil., an associate professor in the immunology program at The Wistar Institute and principal investigator on the study. "Now we're knocking on other doors to try to keep this study on track. Most people, including myself, would never have expected such a crucial study to be in peril at this stage of development."

The reasoning behind the NIH policy is that the high cost of providing drugs for studies would limit the agency's overall capacity for supporting international AIDS research. Also, the agency and researchers alike agree that an important ethical consideration is to address this issue of providing continuing access after a study to the live-saving drugs offered in the course of the study. Although there are different ways to address this concern, all agree that the additional costs of ongoing care for study participants must be factored into the planning for such studies.

If Montaner's study is derailed by the team's inability to find additional funding to purchase the needed drugs, a significant opportunity may be delayed or lost.

In the last four years, Montaner and his colleagues have shown in a U.S. clinical trial that cycles of brief interruptions of anti-HIV drug therapy do not lead to adverse medical outcomes of any kind. A structured start-and-stop regimen allows patients to suppress their HIV infections effectively while on therapy and maintain their immune systems while not giving rise to drug-resistant strains of the virus. The data from this clinical trial underpinned the NIH's approval of the South Africa trial.
-end-
The institutions involved in the study are The Wistar Institute and the University of Pennsylvania in the U.S. and the University of Witwatersrand and the National Institute for Communicable Diseases in South Africa.

The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the causes and cures for major diseases, including cancer, cardiovascular disease, autoimmune disorders, and infectious diseases. Founded in 1892 as the first institution of its kind in the nation, The Wistar Institute today is a National Cancer Institute-designated Cancer Center - one of only eight focused on basic research. Discoveries at Wistar have led to the development of vaccines for such diseases as rabies and rubella, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

News releases from The Wistar Institute are available to reporters by direct e-mail or fax upon request. They are also posted electronically to Wistar's home page (http://www.wistar.upenn.edu)and to EurekAlert! (http://www.eurekalert.org), an Internet resource sponsored by the American Association for the Advancement of Science.

The Wistar Institute

Related HIV Infection Articles from Brightsurf:

Scientists pinpoint new mechanism that impacts HIV infection
A team of scientists led by Texas Biomed's Assistant Professor Smita Kulkarni, Ph.D. and Mary Carrington, Ph.D., at the Frederick National Laboratory for Cancer Research, published results of a study that pinpointed a long noncoding RNA molecule which influences a key receptor involved in HIV infection and progression of the disease.

HIV: Reprogramming cells to control infection
Following research on cohorts, scientists from the Institut Pasteur have described the characteristics of CD8 immune cells in these 'HIV controller' subjects.

USPSTF recommendation on screening for HIV infection
The US Preventive Services Task Force (USPSTF) recommends screening for HIV infection in adolescents and adults ages 15 to 65; in those younger or older at increased risk of infection; and in all pregnant people.

HIV/tuberculosis co-infection: Tunneling towards better diagnosis
1.2 million people in the world are co-infected by the bacteria which causes tuberculosis and AIDS.

HIV vaccine protects non-human primates from infection
New research shows that an experimental HIV vaccine strategy works in non-human primates.

New guidelines for treatment and prevention of HIV infection in adults
Experts have updated recommendations for the use of antiretroviral drugs in the treatment and prevention of HIV infection.

Updated recommendations for treating, preventing HIV infection
A volunteer panel of experts in HIV research and patient care evaluated new data and treatments to update recommendations from the International Antiviral Society-USA for the use of antiretroviral drugs in this special communication article.

Tracking down T cell targets to tamp down HIV infection
Scientists have narrowed in on a group of gut-residing immune cells that might predispose women to increased HIV infection risk and more severe disease.

Two antibodies are better than one for preventing HIV infection
A cocktail of two broadly-neutralizing HIV-1 antibodies (bNAbs) protected primates against infection with a mixed population of HIV viruses -- conditions that mimic real-world transmission -- researchers report.

Novel approach to track HIV infection
Scientists used a novel live-cell fluorescent imaging system that allowed them for the first time to identify individual viral particles associated with HIV infection.

Read More: HIV Infection News and HIV Infection Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.